Advanced in Agranulocytosis

Kunwei W. Shen

197 Ruijin Second Road, 
Shanghai, CN 
Advanced in Agranulocytosis
197 Ruijin Second Road, 
Shanghai, CN 
OverviewLocationsClinical Research

Overview

Kunwei Shen practices in Shanghai, China. Shen is rated as an Advanced expert by MediFind in the treatment of Agranulocytosis. Their top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, Agranulocytosis, HER-2 Positive Breast Cancer, and Mastectomy.

Their clinical research consists of co-authoring 168 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 7 articles in the study of Agranulocytosis.

Locations

197 Ruijin Second Road, Shanghai, 200025, China
Other Locations
197 Ruijin Er Road, Huangpu, 200025, China
Shanghai Jiaotong University 197 Ruijin Second Road, Shanghai, 200025, China
Chinese Academy Of Medical Sciences And Peking Union Medical College, Beijing, 100730, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
Safety of Ovarian Function Suppression(OFS)Combined With Different Aromatase Inhibitors(AIs) Endocrine Therapy in Chinese Premenopausal Breast Cancer Patients：A Randomized, Controlled, Prospective, Observational Study
Safety of Ovarian Function Suppression(OFS)Combined With Different Aromatase Inhibitors(AIs) Endocrine Therapy in Chinese Premenopausal Breast Cancer Patients：A Randomized, Controlled, Prospective, Observational Study
Enrollment Status: Completed
Publish Date: December 30, 2022
Intervention Type: Drug
Study Drugs: OFS + Anastrozole, OFS + Exemestane
Study Phase: Phase 2
Decitabine Plus Carboplatin in the Treatment of Metastatic Triple Negative Breast Cancer
Decitabine Plus Carboplatin in the Treatment of Metastatic Triple Negative Breast Cancer
Enrollment Status: Terminated
Publish Date: April 06, 2022
Intervention Type: Drug
Study Drugs: Decitabine, Carboplatin
Study Phase: Phase 2
Neoadjuvant Treatment of TEC Versus TEC Plus Metformin in Breast Cancer：A Prospective, Randomized Trial
Neoadjuvant Treatment of TEC Versus TEC Plus Metformin in Breast Cancer：A Prospective, Randomized Trial
Enrollment Status: Terminated
Publish Date: April 06, 2022
Intervention Type: Drug
Study Drugs: Metformin, Docetaxel, Epirubicin, Cyclophosphomide
Study Phase: Phase 2
Clinical Study of Adjuvant Therapy on Post-menopausal Women With Breast Cancer Under the Guidance of the Results of Preoperative Endocrinotherapy
Clinical Study of Adjuvant Therapy on Post-menopausal Women With Breast Cancer Under the Guidance of the Results of Preoperative Endocrinotherapy
Enrollment Status: Unknown
Publish Date: November 29, 2021
Intervention Type: Drug
Study Drugs: AI adjuvant therapy, Chemotherapy
Study Phase: Phase 2
A Randomised, Multicenter, Open-label, Phase II Study Evaluating Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in Early Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2 - Positive Breast Cancer
A Randomised, Multicenter, Open-label, Phase II Study Evaluating Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in Early Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2 - Positive Breast Cancer
Enrollment Status: Terminated
Publish Date: May 19, 2020
Intervention Type: Procedure, Drug
Study Phase: Phase 2
Traditional Chinese Medicine as Preventive Method for Osteoporosis in Early Breast Cancer Patients Receiving Adjuvant Endocrine Therapy
Traditional Chinese Medicine as Preventive Method for Osteoporosis in Early Breast Cancer Patients Receiving Adjuvant Endocrine Therapy
Enrollment Status: Completed
Publish Date: April 14, 2020
Intervention Type: Drug
Study Phase: Phase 2
Safety of Toremifene and Tamoxifen Therapy in Premenopausal Patients With Operable Breast Cancer: A Randomized, Controlled, Prospective, Observational Study
Safety of Toremifene and Tamoxifen Therapy in Premenopausal Patients With Operable Breast Cancer: A Randomized, Controlled, Prospective, Observational Study
Enrollment Status: Completed
Publish Date: September 24, 2019
Intervention Type: Drug
Study Phase: Phase 4
View 7 Less Clinical Trials

168 Total Publications

Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial.
Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 09, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Shen's expertise for a condition
ConditionClose
View All 10 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile